CSL shares down 5% after post-heart attack drug disappoints in late-stage test
CSL’s cholesterol efflux enhancer failed to prevent repeat cardiac events in a Phase III study that recruited patients who had a recent myocardial infarction, prompting a drop in the company’s share price.
The Phase III AEGIS-II trial tested the drug, CSL112, against placebo in more than 18,200 patients in the 90-day high-risk period after a heart attack. The treatment missed the primary endpoint of reducing major adverse cardiovascular events (MACE) at 90 days. There were no major safety or tolerability concerns, CSL said in a company release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
